Jazz Pharmaceuticals plc JAZZ

JAZZ Company Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for sleep disorders, oncology, and neuroscience. The company operates within the specialty pharmaceutical and biotechnology industries, targeting areas of high unmet medical need with differentiated therapies. Its primary revenue drivers are prescription medicines addressing narcolepsy and other sleep disorders, as well as hematologic and solid tumor cancers. Jazz serves healthcare providers, hospitals, and specialty pharmacies, with patients as the ultimate end users.

The company’s strategic positioning is built on a combination of internally developed products and externally acquired assets that extend its therapeutic reach. Founded in 2003 and initially headquartered in the United States, Jazz completed a corporate reorganization and became an Irish-domiciled public limited company in 2012. Over time, it evolved from a single-product-focused organization into a diversified biopharmaceutical company through targeted acquisitions, expanded R&D investment, and international commercialization capabilities.